News & Perspective

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 14, 2007

Nov 14, 2007

Study finds greater, later role for antivirals in flu patients

(CIDRAP News) – Adults who are hospitalized with serious seasonal influenza infections are more likely to survive if they receive antiviral medications, and older patients may benefit even if treatment is delayed until more than 48 hours after their first symptoms, according to a new study by Canadian researchers.

Nov 02, 2007

Nov 02, 2007

THE PANDEMIC VACCINE PUZZLE Part 7: Time for a vaccine 'Manhattan Project'?

Editor's note: This is the last in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.

Apr 10, 2007

Apr 10, 2007

FDA may loosen labeling rules for irradiated foods

(CIDRAP News) – The US Food and Drug Administration (FDA) recently proposed rules that would relax some labeling restrictions on irradiated foods and invited the public to comment.

The FDA currently requires all irradiated foods to have the international radura symbol and the statement "treated by irradiation" or "treated with radiation" clearly displayed on the packaging.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»